Physician profile
Ari B Geller
NPI 1710927892
$209,475.17
in general payments reported to CMS, 2019-2025
28 companies · $83K in 2025
The $83K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,686 · 2021: $4,343 · 2022: $18K · 2023: $18K · 2024: $63K · 2025: $83K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $7,074 · Food and Beverage: $6,309 · Consulting Fee: $3,405 · Education: $45.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,384.00 |
| Travel and Lodging | $7,073.95 |
| Food and Beverage | $6,308.93 |
| Consulting Fee | $3,405.00 |
| Education | $45.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $81,398.49 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $57,569.82 | 2022-2025 | Terlivaz |
| Akebia Therapeutics INC | $26,401.13 | 2020-2025 | Vafseo |
| Lilly USA, LLC | $25,457.66 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,585.14 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $5,069.24 | 2022-2025 | Veltassa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $245.69 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $244.05 | 2020-2025 | Filspari |
| Medtronic, INC. | $228.74 | 2024-2025 | Symplicity G3, Ellipsys Vascular Access System |
| Amgen INC. | $215.22 | 2019-2025 | Krystexxa, Parsabiv, Tavneos |
| Baxter Healthcare | $151.98 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $135.26 | 2022-2024 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $114.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $113.08 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $100.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $80.81 | 2024-2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $62.14 | 2025 | |
| Glaxosmithkline, LLC. | $57.16 | 2022-2023 | Benlysta |
| Ardelyx, INC. | $43.05 | 2023-2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $38.57 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $28.96 | 2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $27.24 | 2025 | |
| Horizon Therapeutics Plc | $26.23 | 2023 | Krystexxa |
| Shire North American Group INC | $24.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $20.62 | 2021 | |
| Verona Pharma, INC. | $19.42 | 2025 | Ohtuvayre |
| Mallinckrodt Enterprises LLC | $16.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.